//Your Connection to the Life Sciences Industry
Connect to IBC:LinkedIn iconTwitter iconFacebook iconBlog iconRSS icon

TIDES: Oligonucleotide and Peptide Therapeutics


Agenda CSS

April 30-03, 2017
Manchester Grand Hyatt San Diego
San Diego, CA

Scientific Advisory Board

Scientific Advisory Board

Meet the TIDES 2016 Scientific Advisory Board

  • Kathryn L. Ackley, Ph.D., RAC, Vice President of Development, Nitto Denko Avecia, Inc.
  • Firoz Antia, Ph.D., Director, Chemical Process R&D, Biogen
  • Mimoun Ayoub, Ph.D., Director, Global Peptides and Injectables, Corden Pharma, Switzerland
  • Neil H. Baine, Ph.D., President, Neil Baine Consulting, LLC, and Past Executive Director, Scinovo, Preclinical Development, GlaxoSmithKline Pharmaceuticals
  • Doug Brooks, Ph.D., Vice President, Manufacturing Development, Ophthotech Corporation
  • Bob D. Brown, Ph.D., Chief Scientific Officer and Senior Vice President, Research, Dicerna Pharmaceuticals
  • David Brown, Ph.D., Director, Discovery and in vivo Research, Mirna Therapeutics, Inc.
  • Waleed Danho, Ph.D., Consultant
  • Jesse Z. Dong, Ph.D., Vice President, Peptide Chemistry, Neon Therapeutics
  • Alex Fässler, Ph.D., COO Europe, Bachem AG, Switzerland
  • Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, Quark Pharmaceuticals, Israel
  • Chris Holmes, Ph.D., Former Vice President, Chemical and Pharmaceutical Development, Regado Biosciences
  • Peter Hoffmann, Ph.D.
  • Troels Koch, Ph.D., Vice President, Research and CTO, Roche Innovation Center Copenhagen, Denmark
  • David Litzinger, Ph.D., President, David Litzinger and Associates, LLC
  • John P. Mayer, Ph.D., Senior Research Scientist, Department of Chemistry, Indiana University
  • Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, Inc.
  • Paul McCormac, Ph.D., Director, Biomanufacturing Sciences Group, Pfizer Global Manufacturing
  • Michael McGinley, Senior Product Manager, BioSeparations, Phenomenex
  • Bruce Morimoto, Ph.D., Executive Director Applied Translational Medicine, Drug Development Services, Celerion
  • Gary F. Musso, Ph.D., President, Musso and Associates LLC
  • Lubomir V. Nechev, Ph.D., Vice President, Process Sciences, Alnylam Pharmaceuticals, Inc.
  • Pamela Pavco, Ph.D., Chief Development Officer, RXi Pharmaceuticals
  • El Djouhar Rekaï, Head of Peptide Products Operation, Lonza, Belgium
  • Claus Rentel, Ph.D., Executive Director, Analytical Development/Quality Control, Ionis Pharmaceuticals, Inc.
  • Christopher A. Rhodes, Ph.D., President and CEO, Drug Delivery Experts
  • Christoph Rosenbohm, Ph.D., Senior Director, Research Operations, Roche Innovation Center Copenhagen, Denmark
  • Dmitry Samarsky, Ph.D., SVP, International Business and Technology Development, RiboBio, China
  • Tomi Sawyer, Ph.D., Distinguished Scientist & Head, Peptide Drug Discovery and Innovative Technologies, Merck Research Laboratories
  • Trishul Shah, Associate Director, Business Development, North America, PolyPeptide Laboratories
  • Ved Srivastava, Ph.D., Vice President of Chemistry, Intarcia Therapeutics, Inc.
  • G. Susan Srivatsa, Ph.D., President, ElixinPharma
  • James D. Thompson, Ph.D., Head, CMC and Analytical Development, Moderna Therapeutics, Inc.
  • Peter Timmerman, Ph.D., Chief Scientific Officer, Pepscan Therapeutics, The Netherlands
  • Blake Unterreiner, Business Development Manager, Nucleic Acid Solutions Division, Agilent Technologies, Inc.
  • Thomas Vorherr, Ph.D., Director Peptide Discovery, Novartis Pharma AG, Switzerland
  • Paul Watt, Ph.D., Chief Scientific Officer, Phylogica Ltd., Australia
  • Fran Wincott, Ph.D., President, Wincott & Associates, LLC